Search

Author/Creator Pavlick, Anna C

1. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Issue 11 (November 2016)

Authors:
Hodi, F Stephen; Chesney, Jason; Pavlick, Anna C; Robert, Caroline; Grossmann, Kenneth F; McDermott, David F; Linette, Gerald P; Meyer, Nicolas; Giguere, Jeffrey K; Agarwala, Sanjiv S; Shaheen, Montaser; Ernstoff, Marc S; Minor, David R; Salama, April K; Taylor, Matthew H; Ott, Patrick A; Horak, ...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 11(2016:Nov.)
Page Start:
1558
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Issue 12 (December 2021)

Authors:
Tawbi, Hussein A; Forsyth, Peter A; Hodi, F Stephen; Algazi, Alain P; Hamid, Omid; Lao, Christopher D; Moschos, Stergios J; Atkins, Michael B; Lewis, Karl; Postow, Michael A; Thomas, Reena P; Glaspy, John; Jang, Sekwon; Khushalani, Nikhil I; Pavlick, Anna C; Ernstoff, Marc S; Reardon, David A; Ku...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 12(2021)
Page Start:
1692
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗